Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT02336503 · ClinicalTrials.gov registry record · Phase 2
A Safety and Efficacy Study of BBI-4000 in Subjects With Axillary Hyperhidrosis
A Phase 2 study of Hyperhidrosis, sponsored by Botanix Pharmaceuticals.
- Completed
- Registry status
- Phase 2
- Development phase
- 189
- Enrollment target
- 12
- Study locations
NCT02336503: Completed Phase 2 study of Hyperhidrosis, sponsored by Botanix Pharmaceuticals.
NCT02336503 is a Phase 2 study of Hyperhidrosis that has completed, run by Botanix Pharmaceuticals. The registered enrollment target is 189 participants, above the 76-participant average among 8 other Hyperhidrosis trials with a reported enrollment target (149% higher). The trial reports 12 study locations across 8 states. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT02336503, a Phase 2 study of Hyperhidrosis, has completed, sponsored by Botanix Pharmaceuticals.
- COMPLETED
- Registry status
- Phase 2
- Development phase
- 189 participants
- Enrollment target
- 12
- Study locations
Study Summary
To assess the safety and efficacy of 3 doses of BBI-4000 and vehicle (4 treatment arms), when applied once a day for 4 weeks, for the treatment of axillary hyperhidrosis.
Primary Outcome
Severity is scored with increasing scale, scores 1-4 where minimal severity is scored: 1=My sweating is never noticeable and never interferes with my daily activities and most severe score is: 4=My sweating is intolerable and always interferes with my daily activities
Conditions Studied
Interventions
- DRUG Vehicle
- DRUG BBI-4000 Gel, 5%
- DRUG BBI-4000 Gel, 10%
- DRUG BBI-4000 Gel, 15%
Study Locations (12)
Florida
- Center for Clinical and Cosmetic Research - Aventura
- International Dermatology Research, Inc. - Miami
- International Clinical Research - Sanford
California
- Center for Dermatology Clinical Research, Inc. - Fremont
- Therapeutics Clinical Research - San Diego
Indiana
- Shideler Clinical Research Center - Carmel
- The Indiana Clinical Trials Center - Plainfield
Minnesota
- Minnesota Clinical Study Center - Fridley
Missouri
- Saint Louis University Dermatology - St Louis
New Mexico
- Academic Dermatology Associates - Albuquerque
Texas
- The Center for Skin Research - Houston
Virginia
- Virginia Clinical Research, Inc. - Norfolk
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 189 participants |
| Start Date | 2015-03-10 |
| Est. Completion | 2015-11-05 |
| Phase | Phase 2 |
What the finished NCT02336503 record still lists
NCT02336503 is an interventional study that assigns participants to a tested intervention. The registered 189 participants enrollment target is mid-sized for trials with a published cap, above the 76-participant average among 8 other Hyperhidrosis trials with a reported enrollment target (149% higher).
The record links to 1 condition, with Hyperhidrosis appearing as the primary indexed condition, and to 4 interventions - of which Vehicle is the first listed.
NCT02336503 lists 12 locations in 8 states (Florida, California, Indiana).
Frequently Asked Questions
What is clinical trial NCT02336503 about?
NCT02336503 is a clinical study titled "A Safety and Efficacy Study of BBI-4000 in Subjects With Axillary Hyperhidrosis". To assess the safety and efficacy of 3 doses of BBI-4000 and vehicle (4 treatment arms), when applied once a day for 4 weeks, for the treatment of axillary hyperhidrosis.
What is the current status of trial NCT02336503?
This trial is currently completed. It is a Phase 2 study. The enrollment target is 189 participants. The study started on 2015-03-10. Estimated completion is 2015-11-05.
What conditions does trial NCT02336503 study?
This clinical trial studies the following conditions: Hyperhidrosis.
What interventions are being tested in trial NCT02336503?
The interventions under investigation include: Vehicle (DRUG), BBI-4000 Gel, 5% (DRUG), BBI-4000 Gel, 10% (DRUG), BBI-4000 Gel, 15% (DRUG).
Who is sponsoring clinical trial NCT02336503?
This trial is sponsored by Botanix Pharmaceuticals, which has 9 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT02336503 being conducted?
This trial has 12 study locations across California, Florida, Indiana, Minnesota, Missouri. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Hyperhidrosis
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
Where NCT02336503's enrollment target sits among peer trials
189 2nd of 8 the highest of 8 other Hyperhidrosis trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other Hyperhidrosis trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
-
Safety and Efficacy of Botulinum Toxin Type A Topical Gel for Primary Axillary Hyperhidrosis
COMPLETED · Phase 2
-
Safety and Efficacy of an Anticholinergic Agent for Treatment of Primary Axillary Hyperhidrosis
COMPLETED · Phase 2
-
A Study to Evaluate Clinical Effect, Pharmacokinetics , Safety, and Tolerability of Umeclidinium in Palmar Hyperhidrosis Subjects
COMPLETED · Phase 2
-
An Open Label Study for Palmar Hyperhydrosis
COMPLETED · Phase 2
-
Comparator Study of the Effect of Glycopyrrolate and Glycopyrronium in Subjects With Axillary Hyperhidrosis
COMPLETED · Phase 2
-
Botulinum Toxin Therapy in Hidradenitis Suppurativa
RECRUITING
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT02734537 · 189 participants · Phase 2
Radiation Therapy With or Without Cisplatin in Treating Patients With Stage III-IVA Squamous Cell Carcinoma of the Head and Neck Who Have Undergone Surgery
- NCT05058651 · 189 participants · Phase 2
Evaluating the Addition of the Immunotherapy Drug Atezolizumab to Standard Chemotherapy Treatment for Advanced or Metastatic Neuroendocrine Carcinomas That Originate Outside the Lung
- NCT05673408 · 189 participants
NIBP Validation Study
- NCT05994209 · 189 participants · Phase 1
Testing the Feasibility and Acceptability of Social Media and Digital Therapeutics to Decrease Vaping Behaviors
Similar registry start date
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia
- NCT07125183 · started 2026-12 · Phase 2
Study on Efficacy and Tolerability of Weekly Doxorubicin in Elderly Patients With Advanced or Metastatic Leiomyosarcoma
- NCT07292298 · started 2026-11 · Phase 2
Phase 2 Single-Arm Rectal Cancer Brachytherapy for Patients With Low-Lying Residual Adenocarcinoma After Total Neoadjuvant Therapy to Improve Organ Preservation Rates
- NCT04263285 · started 2026-10 · NA
Treatment of Depression Post-SCI